Alendronate may have a beneficial effect on muscle mass in addition to its well known positive effect on bone mass, hint preliminary findings from Japan. According to Dr. Atsushi Harada from the National Center for Geriatrics & Gerontology in Aichi, there is growing evidence of a functional musclebone unit in which bone health may be […]
The European Medicines Agency (EMA) has recommended the approval a specific antidote to reverse the anticoagulant effect of the direct oral thrombin inhibitor dabigatran (Pradaxa): idarucizumab (Praxbind, Boehringer Ingelheim).
According a new research, overingestion of two factor Xa inhibitors is rarely associated with serious bleeding in adults — and has no association with toxicity in kids who accidently take the drugs.
Metformin-related vitamin B12 deficiency might contribute to clinically significant peripheral neuropathy in diabetes patients, new research suggests.
Exposure to pesticides significantly increases the risk of type 2 diabetes by nearly 60%, finds an extensive literature review presented at the the European Association for the Study of Diabetes 2015 Meeting last week.
A new report provides details on 45 individuals from 13 countries who developed a chronic ailment soon after receiving the human papillomavirus (HPV) vaccine.
A reanalysis of the now infamous Study 329 of the antidepressant paroxetine (multiple brands) shows that the drug is ineffective and unsafe for adolescents, prompting experts to call for a retraction of the original study.
Insulin degludec/liraglutide has proven to be superior to insulin glargine in hemoglobin A1c reduction, risk of hypoglycemia, and weight reduction in the DUAL V study. This result of the open-label DUAL V trial was reported at the Annual Meeting of the European Association for the Study of Diabetes 2015.
According to a new research, the risk of pancreatic cancer was not elevated with incretin-based drugs compared with other glucose-lowering therapies.
Glyburide is associated with an increased risk for cancer compared with other diabetes drugs of the sulfonylurea class, new research suggests. Previous observational studies have linked the use of sulfonylureas in general to an increased risk of cancer, but only a few studies have examined the association by type of sulfonylurea, the authors explain.
Another trial of extended clopidogrel has done little to settle the confusion about how long dual antiplatelet therapy should be continued following drug-eluting–stent (DES) placement, with one commentator saying the studies available on this topic were like “the blind leading the deaf.”